This trial is testing whether it is safe to give a certain type of cell, called mesenchymal stromal cells (MSCs), to kidney transplant recipients. The combination of the immunosuppressive (anti-rejection) study drugs plus the MSCs might allow a kidney transplant recipient to slowly reduce and/or then completely stop all anti-rejection drugs, without rejection of their kidney (renal) allograft, a process called "immunosuppression withdrawal".